SkinBioTherapeutics plc (LON:SBTX – Get Free Report) shares reached a new 52-week low on Monday. The stock traded as low as GBX 4.50 and last traded at GBX 4.65, with a volume of 42,743 shares. The stock had previously closed at GBX 4.67.
SkinBioTherapeutics Trading Down 0.4%
The company has a debt-to-equity ratio of 11.77, a quick ratio of 10.01 and a current ratio of 6.14. The business’s 50 day moving average price is GBX 6.29 and its 200-day moving average price is GBX 9.55. The firm has a market cap of £12.05 million, a price-to-earnings ratio of -29.06 and a beta of 0.10.
About SkinBioTherapeutics
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
Recommended Stories
- Five stocks we like better than SkinBioTherapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
